Physician profile
Ben Gregory Bostick
NPI 1518948215
$4,839.39
in general payments reported to CMS, 2019-2025
35 companies · $182 in 2025
The $182 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,093 · 2020: $979 · 2021: $778 · 2022: $729 · 2023: $795 · 2024: $284 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,260.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,108.54 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $552.48 | 2019-2024 | Airsupra, Farxiga |
| Novo Nordisk INC | $453.73 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $419.48 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $405.38 | 2019-2023 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $237.54 | 2019-2023 | Xarelto |
| Abbvie INC. | $224.52 | 2021-2023 | Vraylar, Ubrelvy |
| Amgen INC. | $161.01 | 2019-2025 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $160.32 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.33 | 2019-2023 | Synjardy, Jardiance, Tradjenta |
| Merck Sharp & Dohme LLC | $133.24 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.17 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $111.95 | 2020-2023 | Eliquis |
| Amarin Pharma, INC. | $85.78 | 2019-2020 | |
| Lilly USA, LLC | $74.42 | 2022-2024 | Jardiance, Mounjaro |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $69.63 | 2023-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $59.47 | 2019-2021 | |
| Exact Sciences Corporation | $56.44 | 2023-2025 | Cologuard Collection Kit |
| Eisai INC. | $35.99 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.15 | 2022-2024 | |
| Mylan Specialty L.P. | $29.66 | 2022-2023 | Yupelri |
| Genzyme Corporation | $28.42 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $20.43 | 2025 | Rexulti |
| Abbott Laboratories | $17.84 | 2023 | Freestyle Libre 2 |
| Lundbeck LLC | $15.58 | 2024 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $14.71 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.41 | 2024 | Voquezna |
| Allergan, INC. | $14.25 | 2019 | |
| Sumitomo Pharma America, INC. | $12.59 | 2023 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $12.07 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.86 | 2022 | |
| Sunovion Pharmaceuticals INC. | $11.00 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ben Bostick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.